|Page (1) of 1 - 10/18/11||email article||print page|
Stem Cell Research Mired in Controversy -- AgainThe Paragon Report Provides Equity Research on Geron Corporation & Cytori Therapeutics (October 18, 2011)
NEW YORK, NY -- (Marketwire) -- 10/18/11 -- Stem Cell stocks continue to be some of the most volatile in the market. While scientists firmly believe that stem cells are the future of medicine, and a highly lucrative sector, investors worry that budget cuts could slash funding for the controversial research. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Geron Corporation (NASDAQ: GERN) and Cytori Therapeutics, Inc. (NASDAQ: CYTX). Access to the full company reports can be found at:
Embryonic stems cell research suffers on-again, off-again bans on US federal funding. Since Obama took office, funding has been less sporadic. However last month two scientists appealed a ruling that permitted federal funding of human embryonic stem research to go forward. Dr. James Sherley, a biological engineer at Boston Biomedical Research Institute, and Theresa Deisher, of Washington-based AVM Biotechnology argued it diverted money away from their work with adult stem cells.
Embryonic stem cells come from days-old human embryos and can produce any type of cell in the body. Scientists hope to be able to use them to address spinal cord injuries, cancer, diabetes, Alzheimer's, Parkinson's and much more.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Adult stem cells, well significantly less controversial, may only develop into a limited number of cell types, so their potential applications are not as great as embryonic stem cells. Cytori is a leader in cell therapy, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue.
Presently Geron is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
Copyright @ Marketwire
Related Keywords: Paragon Report, Research Reports, Analyst Reports, Equity Research, Stock Market, Investment, Marketwire, Inc., , Medical, Biology, Engineering, Stem Cell, Cancer, Other,